MaxCyte (MXCT) Share Price, News & Analysis

Company Overview

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions. Let’s Build Better Cells Together. To learn more, please visit www.maxcyte.com

Key Stats

• Today's Range: 206 to 226
• 50-Day Range: 220 to 404
• 52-Week Range: 206 to 410
• Volume: 85,730 shs
• Average Volume: 43,161 shs
• Market Capitalization: £271.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MXCT Stock Analysis - Frequently Asked Questions

How have MXCT shares performed this year?

MaxCyte's stock was trading at GBX 321.20 at the start of the year. Since then, MXCT shares have decreased by 33.4% and is now trading at GBX 214.
View the best growth stocks for 2025 here.

How do I buy shares of MaxCyte?

Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include HSBC (HSBA), Royal Dutch Shell (RDSB), Cassava Sciences (SAVA), EQTEC (EQT), Grafton Group (GFTU), Lloyds Banking Group (LLOY) and Marks and Spencer Group (MKS).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: Business Services
• Current Symbol: LON:MXCT
• CIK: N/A
• Web: www.maxcyte.com
• Phone: +1-301-9441700
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (27.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-45,081,271.80
• Net Margins: -78.37%
• Pretax Margin: N/A
• Return on Equity: -16.01%
• Return on Assets: -11.07%

Debt

• Debt-to-Equity Ratio: 8.59
• Current Ratio: 9.81
• Quick Ratio: 14.38

Sales & Book Value

• Annual Sales: £57.52 million
• Price / Sales: 5.05
• Cash Flow: GBX 111.56 per share
• Price / Cash Flow: 1.97
• Book Value: GBX 203.85 per share
• Price / Book: 1.08

Miscellaneous

• Outstanding Shares: 132,004,040
• Free Float: N/A
• Market Cap: £290.41 million
• Optionable: Not Optionable
• Beta: 1.13